Sofosbuvir plus ribavirin and sofosbuvir plus daclatasvir-based regimens are suboptimal in genotype 2 patients: real-life experience

Authors :: Georges Haour
V. de Ledinghen
Dominique Larrey
Christophe Hézode
D. Celine
Pol Stanislas
J.-M. Pawlotsky
Tran Albert
Olivier Chazouillères
Metivier Sophie
M. Patrick
Didier Samuel
F. Helene
C. Fabrice
Fabien Zoulim
C. Stephane
Jean-Pierre Bronowicki
Source :: Journal of Hepatology. 68:S264
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: Oncology
medicine.medical_specialty
Daclatasvir
Hepatology
Sofosbuvir
business.industry
Ribavirin
chemistry.chemical_compound
chemistry
Internal medicine
Genotype
Medicine
business
medicine.drug

Full Text Access

Tools